SEC Comment Letter 0000000000-25-003340 to Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc.
Date: March 28, 2025 · CIK: 0001802665 · Accession: 0000000000-25-003340
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Harmony Biosciences Holdings, Inc. Form10-K for Fiscal Year Ended December 31 , 2024 Form 8-K Dated February 25, 2025 Dear Sandip Kapadia:
March 28, 2025
Sandip Kapadia Chief Financial Officer Harmony Biosciences Holdings, Inc. 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462
We have limited our review of your filing to the financial statements and related disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 8-K Dated February 25, 2025 Exhibit 99.1
1. We note your non-GAAP adjusted net income includes adjustments for upfront licensing fees, milestone payments and IPR&D charges incurred in connection with asset acquisitions. Please tell us how you determined that these adjustments do not represent normal, recurring, cash operating expenses necessary to operate your business. Refer to Question 100.01 of the Compliance & Disclosure Interpretations on Non-GAAP Financial Measures.
In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. March 28, 2025 Page 2
Please contact Eric Atallah at 202-551-3663 or Gary Newberry at 202-551-3761 with any questions.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 28, 2025 Sandip Kapadia Chief Financial Officer Harmony Biosciences Holdings, Inc. 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 Re: Harmony Biosciences Holdings, Inc. Form10-K for Fiscal Year Ended December 31 , 2024 Form 8-K Dated February 25, 2025 Dear Sandip Kapadia: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 8-K Dated February 25, 2025 Exhibit 99.1 1. We note your non-GAAP adjusted net income includes adjustments for upfront licensing fees, milestone payments and IPR&D charges incurred in connection with asset acquisitions. Please tell us how you determined that these adjustments do not represent normal, recurring, cash operating expenses necessary to operate your business. Refer to Question 100.01 of the Compliance & Disclosure Interpretations on Non-GAAP Financial Measures. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. March 28, 2025 Page 2 Please contact Eric Atallah at 202-551-3663 or Gary Newberry at 202-551-3761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>